Description: <b>Cannabichromene (CBC)</b> is a phytocannabinoid found in the Cannabis plant. It has anti-inflammatory, antitumor and anticonvulsant properties, and may affect THC psychoactivity.<br>
<p><b>Cannabichromene</b> (CBC) is a non-psychotropic phytocannabinoid produced by <i>Cannabis sativa</i> through decarboxylation of cannabichromenic acid (CBCA). It is formally classified as a plant-derived small-molecule cannabinoid and, in oncology, is best considered an exploratory adjunctive natural product rather than an established anticancer drug. Standard abbreviation: CBC. Current evidence supports a receptor-mixed pharmacology centered on CB2-preferring signaling, TRPA1 activity, and modulation of endocannabinoid tone, but the human evidence base remains sparse. </p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>CB2 receptor agonism with predominantly anti-inflammatory and immunomodulatory signaling</li>
<li>TRPA1 activation and subsequent desensitization, relevant to inflammatory and nociceptive modulation</li>
<li>Endocannabinoid tone modulation through inhibition of endocannabinoid cellular uptake and weak MAGL inhibition</li>
<li>Suppression of inflammatory nitric oxide output in activated macrophages</li>
<li>Context-dependent antiproliferative and pro-apoptotic effects in cannabinoid-containing extract systems, with CBC often acting as one component rather than a fully validated stand-alone anticancer effector</li>
<li>Clinical translation constraint from variable oral exposure, first-pass metabolism, formulation dependence, and limited human efficacy data</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> CBC is lipophilic and formulation-sensitive. Human oral PK data exist, but mainly from mixed cannabinoid oil products rather than purified CBC. Oral exposure is variable, first-pass metabolism is relevant, and current PK reviews identify low/variable bioavailability and limited clinical PK characterization as major translational constraints.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is an important limitation. Mechanistic and antiproliferative findings are mainly preclinical, and many in-vitro cannabinoid concentrations used in oncology-oriented studies are likely above readily achievable systemic exposure with currently described oral human CBC dosing. CBC is therefore more plausible at present as a pharmacology signal or adjunctive lead than as a validated concentration-achievable stand-alone anticancer agent.</p>
<p><b>Clinical evidence status:</b> Preclinical and early human PK only. No established CBC-specific randomized oncology efficacy trials were identified. Regulatory/clinical use is not established for purified CBC as an approved anticancer drug.</p>
<h3>Mechanistic interpretation</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>CB2 signaling</td>
<td>↓ inflammatory support signals (context-dependent)</td>
<td>↓ inflammatory activation</td>
<td>R-G</td>
<td>Immunomodulatory anti-inflammatory bias</td>
<td>Best-supported direct receptor mechanism. CBC behaves as a selective CB2 agonist with little meaningful CB1 activity in the cited receptor studies. Anticancer leverage is indirect and context-dependent rather than firmly cytotoxic.</td>
</tr>
<tr>
<td>2</td>
<td>TRPA1 activation desensitization</td>
<td>↔ direct tumor kill uncertain</td>
<td>↓ nociceptive and inflammatory signaling</td>
<td>P-R</td>
<td>Sensory-inflammatory modulation</td>
<td>TRPA1 appears mechanistically relevant for CBC pharmacology. In oncology this is more plausible for inflammation/pain biology than for a robust stand-alone tumoricidal mechanism.</td>
</tr>
<tr>
<td>3</td>
<td>Endocannabinoid tone AEA uptake MAGL</td>
<td>↔ mixed</td>
<td>↔ mixed</td>
<td>R-G</td>
<td>Indirect ECS amplification</td>
<td>CBC has been reported to inhibit endocannabinoid cellular reuptake and weakly inhibit MAGL, which could alter local endocannabinoid tone. Net cancer relevance is model-dependent and presently secondary.</td>
</tr>
<tr>
<td>4</td>
<td>Macrophage nitric oxide inflammatory axis</td>
<td>↓ pro-tumor inflammatory milieu (possible)</td>
<td>↓ NO output in activated macrophages</td>
<td>R-G</td>
<td>Anti-inflammatory effector suppression</td>
<td>Strong preclinical evidence shows CBC reduces nitrite / nitric oxide output in activated macrophages and improves murine colitis. This supports anti-inflammatory action but not a CBC-specific clinical anticancer effect.</td>
</tr>
<tr>
<td>5</td>
<td>Apoptosis and migration inhibition</td>
<td>↓ viability; ↓ migration/invasion (extract-dependent)</td>
<td>↔ unknown</td>
<td>G</td>
<td>Preclinical antiproliferative signal</td>
<td>Anticancer findings exist in bladder and other experimental systems, but CBC is often part of active extract fractions or cannabinoid combinations. Attribution to purified CBC alone remains lower-confidence than for its anti-inflammatory pharmacology.</td>
</tr>
<tr>
<td>6</td>
<td>Estrogen receptor antagonism</td>
<td>↓ ER signaling (weak, high concentration only)</td>
<td>↔ uncertain</td>
<td>R</td>
<td>Possible endocrine interaction</td>
<td>Recent breast-cancer-related in vitro work suggests CBC can show ER antagonism at 10 μM, but this is not yet a core validated mechanism and may be influenced by concurrent cell-viability effects.</td>
</tr>
<tr>
<td>7</td>
<td>ROS NRF2</td>
<td>↔ not established as core</td>
<td>↔ not established as core</td>
<td></td>
<td>Not a primary defining axis</td>
<td>ROS/NRF2 are not well established as central CBC mechanisms from current higher-confidence sources, so they should not be foregrounded for this product at present.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>Exposure limitations</td>
<td>Exposure limitations</td>
<td>G</td>
<td>PK and evidence bottleneck</td>
<td>Human PK data show measurable oral exposure, but formulation dependence, first-pass metabolism, sparse monotherapy data, and lack of CBC-specific oncology trials materially limit translation. Many in-vitro oncology concentrations may exceed realistic systemic exposure.</td>
</tr>
</table>
<p>TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr</p>